

Changes in plasma protein binding have little clinical re

Clinical Pharmacology and Therapeutics

71, 115-121

DOI: 10.1067/mcp.2002.121829

Citation Report

#	ARTICLE	IF	CITATIONS
1	Modulation of nonspecific binding in ultrafiltration protein binding studies. <i>Pharmaceutical Research</i> , 2003, 20, 1015-1021.	1.7	102
2	Hepatic drug metabolism and transport in patients with kidney disease. <i>American Journal of Kidney Diseases</i> , 2003, 42, 906-925.	2.1	103
4	Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. <i>Lancet Neurology</i> , The, 2003, 2, 347-356.	4.9	447
5	Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of Erlotinib (Tarceva). <i>Seminars in Oncology</i> , 2003, 30, 25-33.	0.8	81
6	Preclinical Pharmacokinetics and Metabolism of BMS-14778, a Novel Melatonin Receptor Agonist. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 760-772.	1.6	44
7	Drug interactions: a review and update. <i>Endodontic Topics</i> , 2003, 4, 9-21.	0.5	4
8	Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bile. <i>British Journal of Clinical Pharmacology</i> , 2003, 57, 344-348.	1.1	7
9	Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. <i>British Journal of Clinical Pharmacology</i> , 2003, 57, 6-14.	1.1	1,212
10	Making Better Drugs: Decision Gates in Non-Clinical Drug Development. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 542-553.	21.5	219
11	Clinical Pharmacokinetics of Drugs Used to Treat Urge Incontinence. <i>Clinical Pharmacokinetics</i> , 2003, 42, 1243-1285.	1.6	97
12	Warfarin and Amoxicillin/Clavulanate Drug Interaction. <i>Annals of Pharmacotherapy</i> , 2003, 37, 367-370.	0.9	50
13	Protein Binding in Antiretroviral Therapies. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 825-835.	0.5	173
14	Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 1059-1063.	2.5	93
15	Influence of Mild Liver Impairment on the Pharmacokinetics and Metabolism of Bosentan, a Dual Endothelin Receptor Antagonist. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 15-22.	1.0	33
16	Pharmacogenomic considerations in drug delivery. <i>Pharmacogenomics</i> , 2003, 4, 443-461.	0.6	10
17	Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. <i>Cardiovascular Research</i> , 2003, 58, 32-45.	1.8	1,369
18	Hydrophobic and Ionic Factors in the Binding of Local Anesthetics to the Major Variant of Human $\alpha$ 1-Acid Glycoprotein. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 304, 71-80.	1.3	42
19	Factors Involved in the Pharmacokinetics of COL-3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer: Clinical and Experimental Studies. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 1124-1135.	1.0	12

#	ARTICLE	IF	CITATIONS
20	Lack of Methadone Dose Alterations or Withdrawal Symptoms During Therapy With Lopinavir/Ritonavir. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 33, 650-651.	0.9	27
21	Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, ii23-ii28.	1.3	84
22	Aging Biology and Geriatric Clinical Pharmacology. <i>Pharmacological Reviews</i> , 2004, 56, 163-184.	7.1	656
23	Finding time for allosteric interactions. <i>Nature Biotechnology</i> , 2004, 22, 1376-1377.	9.4	6
24	Effect of glycyrrhizic acid on protein binding of diltiazem, verapamil, and nifedipine. <i>Archives of Pharmacal Research</i> , 2004, 27, 978-983.	2.7	13
25	Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 324-330.	2.3	86
26	Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus*1, *2. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 310-323.	2.3	56
27	Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl- $\beta$ -methadol in opioid-naive individuals*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 154-166.	2.3	24
28	Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents. <i>Journal of Clinical Oncology</i> , 2004, 22, 2489-2503.	0.8	423
29	Special Population Studies In Clinical Development: Pharmacokinetic Considerations. , 2004, , 245-305.		1
30	Plasma Protein-Binding Methods in Drug Discovery. , 2004, , 111-122.		11
31	Pharmacokinetics of Ibuprofen in Children with Cystic Fibrosis. <i>Clinical Pharmacokinetics</i> , 2004, 43, 145-156.	1.6	7
32	Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist. <i>Clinical Pharmacokinetics</i> , 2004, 43, 1089-1115.	1.6	229
33	Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles. <i>Cancer Research</i> , 2004, 64, 5804-5811.	0.4	222
34	Isothermal Titration Calorimetry Characterization of Drug-Binding Energetics to Blood Proteins. , 2004, , 123-149.		8
35	Effect of ethanol or/and captopril on the secondary structure of human serum albumin before and after protein binding. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2004, 57, 457-464.	2.0	55
36	Concomitant Administration of Lumiracoxib and a Triphasic Oral Contraceptive Does Not Affect Contraceptive Activity or Pharmacokinetic Profile. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 646-654.	1.0	6
37	Distribution of Diazepam and Nordiazepam Between Plasma and Whole Blood and the Influence of Hematocrit. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 380-385.	1.0	41

#	ARTICLE	IF	CITATIONS
38	The Pharmacokinetic Imperative in Late-Life Depression. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, S19-S23.	0.7	25
39	The Pharmacokinetics and Interactions of New Antiepileptic Drugs. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 722-726.	1.0	44
40	The pH Dependency of the Binding of Drugs to Plasma Proteins in Man. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 71-85.	1.0	61
41	Pharmacodynamics of Propofol during Hemorrhagic Shock. <i>Anesthesiology</i> , 2005, 102, 1068-1069.	1.3	18
43	Relationship of systemic exposure to unbound docetaxel and neutropenia. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 43-53.	2.3	79
44	Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 132-142.	2.3	68
45	Vibrational Spectroscopic Studies on the Disulfide Formation and Secondary Conformational Changes of Captoprilâ€“HSA Mixture after UV-B Irradiation. <i>Photochemistry and Photobiology</i> , 2005, 81, 1404.	1.3	7
46	Kinetics of Interaction of Local Anesthetics with Human Serum Albumin. <i>Bulletin of Experimental Biology and Medicine</i> , 2005, 140, 315-316.	0.3	5
47	Introduction to Drug Interactions. , 2005, , 1-11.		4
48	LC/MS/MS in drug development: targeting the brain. <i>BioTechniques</i> , 2005, 38, S19-S23.	0.8	4
49	Pharmacokinetic dosage guidelines for elderly subjects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005, 1, 33-48.	1.5	19
50	Hypoalbuminaemia and propofol pharmacokinetics. <i>British Journal of Anaesthesia</i> , 2005, 95, 559.	1.5	6
51	Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. <i>British Journal of Anaesthesia</i> , 2005, 95, 524-529.	1.5	42
52	Pharmacokinetic Alterations of Antimicrobials in the Critically Ill. <i>Journal of Pharmacy Practice</i> , 2005, 18, 75-83.	0.5	3
53	Comment: decreased warfarin effect after initiation of high-protein, low-carbohydrate diets. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1371-1372.	0.9	4
54	Sex and Racial Differences in Pharmacological Response: Where Is the Evidence? <i>Pharmacogenetics, Pharmacokinetics, and Pharmacodynamics. Journal of Women's Health</i> , 2005, 14, 19-29.	1.5	250
55	The Clinical Pharmacokinetics of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 987-1003.	1.0	153
56	Protein Binding Characteristics of 2â€“Benzoyloxycinnamaldehyde. <i>Drug Development and Industrial Pharmacy</i> , 2005, 31, 545-549.	0.9	1

#	ARTICLE	IF	CITATIONS
57	Interaction of Warfarin With Drugs, Natural Substances, and Foods. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 127-132.	1.0	162
58	Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids. <i>Clinical Pharmacokinetics</i> , 2005, 44, 61-98.	1.6	655
59	Effect of Impaired Renal Function and Haemodialysis on the Pharmacokinetics of Aprepitant. <i>Clinical Pharmacokinetics</i> , 2005, 44, 637-647.	1.6	24
60	Pregnancy-Induced Changes in Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2005, 44, 989-1008.	1.6	538
61	The pharmacological treatment of neonatal pain. <i>Seminars in Fetal and Neonatal Medicine</i> , 2005, 10, 195-205.	1.1	46
62	Cardiovascular Drug Therapy in Elderly Patients. <i>Drugs and Aging</i> , 2005, 22, 913-941.	1.3	35
63	Pharmacokinetic/Pharmacodynamic Modeling of Anesthetics in Children. <i>Paediatric Drugs</i> , 2006, 8, 139-150.	1.3	26
64	Pharmacokinetics and interactions of headache medications, part I: introduction, pharmacokinetics, metabolism and acute treatments. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 961-979.	1.5	10
66	Pharmacokinetic Changes in Critical Illness. <i>Critical Care Clinics</i> , 2006, 22, 255-271.	1.0	250
67	Distribution "in vitro Tests" Protein Binding. , 2006, , 473-486.		4
68	Pain control: Non-steroidal anti-inflammatory agents. <i>Seminars in Fetal and Neonatal Medicine</i> , 2006, 11, 251-259.	1.1	46
69	Location of High and Low Affinity Fatty Acid Binding Sites on Human Serum Albumin Revealed by NMR Drug-competition Analysis. <i>Journal of Molecular Biology</i> , 2006, 361, 336-351.	2.0	301
70	On the Observed Large Interspecies Overprediction of Human Clearance ("Vertical Allometry") of UCN-01: Further Support for a Proposed Model Based on Plasma Protein Binding. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 398-400.	1.0	14
71	Determination of Amprenavir Total and Unbound Concentrations in Plasma by High-Performance Liquid Chromatography and Ultrafiltration. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 89-94.	1.0	16
72	Reduced valproate plasma levels possible after introduction of efavirenz in a bipolar patient. <i>Bipolar Disorders</i> , 2006, 8, 415-417.	1.1	17
73	Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1502-1509.	1.9	18
74	Interactions of Serum Albumin, Valproic Acid and Carbamazepine with the Pharmacokinetics of Phenytoin in Cancer Patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 99, 133-140.	1.2	20
75	The disposition of lidocaine during a 12-hour intravenous infusion to postoperative horses. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2006, 29, 495-499.	0.6	26

#	ARTICLE	IF	CITATIONS
76	Clinically relevant drug interactions with antiepileptic drugs. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 246-255.	1.1	502
77	Disposition and pharmacodynamics of propofol during isovolaemic haemorrhage followed by crystalloid resuscitation in humans. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 256-261.	1.1	16
78	Drug interactions in cancer therapy. <i>Nature Reviews Cancer</i> , 2006, 6, 546-558.	12.8	290
79	Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 246-256.	2.3	61
80	Orosomucoid ( $\alpha$ 1-acid glycoprotein) plasma concentration and genetic variants: Effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 307-318.	2.3	66
81	Determination of the extent of protein binding of antibiotics by means of an automated continuous ultrafiltration method. <i>International Journal of Pharmaceutics</i> , 2006, 311, 108-112.	2.6	33
82	Predictions of the In Vivo Clearance of Drugs from Rate of Loss Using Human Liver Microsomes for Phase I and Phase II Biotransformations. <i>Pharmaceutical Research</i> , 2006, 23, 654-662.	1.7	54
83	Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 275-281.	1.1	39
84	Influence of propofol concentration in human plasma on free fraction of the drug. <i>Chemico-Biological Interactions</i> , 2006, 159, 149-155.	1.7	29
85	The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat. <i>Biopharmaceutics and Drug Disposition</i> , 2006, 27, 7-16.	1.1	44
86	Using pharmacokinetics to predict the effects of pregnancy and maternal $\rightarrow$ infant transfer of drugs during lactation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 947-960.	1.5	71
87	Antidepressant $\rightarrow$ Drug Interactions are Potentially but Rarely Clinically Significant. <i>Neuropsychopharmacology</i> , 2006, 31, 1594-1604.	2.8	32
88	Influence of acute normovolaemic haemodilution on the dose $\rightarrow$ response relationship, time-course of action and pharmacokinetics of rocuronium bromide. <i>British Journal of Anaesthesia</i> , 2006, 97, 482-488.	1.5	7
89	Population Analysis of Weight-, Age-, and Sex-Related Differences in the Pharmacokinetics of Lopinavir in Children from Birth to 18 Years. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3548-3555.	1.4	67
90	Changes in the effect of propofol in response to altered plasma protein binding during normothermic cardiopulmonary bypass. <i>British Journal of Anaesthesia</i> , 2006, 96, 179-185.	1.5	43
91	Explaining Variability in Mycophenolic Acid Exposure to Optimize Mycophenolate Mofetil Dosing: A Population Pharmacokinetic Meta-Analysis of Mycophenolic Acid in Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 871-880.	3.0	175
92	Bilirubin Unbound: Deja Vu All Over Again?. <i>Pediatrics</i> , 2006, 117, 523-525.	1.0	38
93	Plasma Protein Binding of an Antisense Oligonucleotide Targeting Human ICAM-1 (ISIS 2302). <i>Oligonucleotides</i> , 2006, 16, 169-180.	2.7	113

#	ARTICLE	IF	CITATIONS
94	A Different View on Bilirubin Binding. <i>Pediatrics</i> , 2006, 118, 846-847.	1.0	3
95	IN VITRO BLOOD DISTRIBUTION AND PLASMA PROTEIN BINDING OF THE IRON CHELATOR DEFERASIROX (ICL670) AND ITS IRON COMPLEX FE-[ICL670] <sub>2</sub> FOR RAT, MARMOSSET, RABBIT, MOUSE, DOG, AND HUMAN. <i>Drug Metabolism and Disposition</i> , 2006, 34, 971-975.	1.7	29
96	The Use of Toxicokinetic Data in Preclinical Safety Assessment: A Toxicologic Pathologist Perspective. <i>Toxicologic Pathology</i> , 2007, 35, 834-837.	0.9	18
97	Influence of acute normovolaemic haemodilution on the dose-response relationship and time course of action of cisatracurium besylate. <i>British Journal of Anaesthesia</i> , 2007, 98, 342-346.	1.5	7
98	Marked Strain Differences in the Pharmacokinetics of an $\alpha_1$ Integrin Antagonist, 4-[1-[3-Chloro-4-[N-(2-methylphenyl)-ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl]-methoxybenzoic Acid (D01-4582), in Sprague-Dawley Rats Are Associated with Albumin Genetic Polymorphism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 124-132.	1.3	23
99	Pharmacokinetic-Pharmacodynamic Crisis in the Elderly. <i>American Journal of Therapeutics</i> , 2007, 14, 488-498.	0.5	173
100	Plasma Protein Binding Affinity and Its Relationship to Molecular Structure: An In-silico Analysis. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 101-112.	2.9	101
101	In Vitro Models for Plasma Binding and Tissue Storage. , 2007, , 321-340.		8
102	Extended-Release Formulations for the Treatment of Epilepsy. <i>CNS Drugs</i> , 2007, 21, 765-774.	2.7	67
103	Effect of Time, Injury, Age and Ethanol on Interpatient Variability in Valproic Acid Pharmacokinetics after Traumatic Brain Injury. <i>Clinical Pharmacokinetics</i> , 2007, 46, 307-318.	1.6	10
104	Impact of Erythrocyte Duffy Antigen Genetic Polymorphism on the Distribution of GroB-T, a Novel Human CXC Chemokine. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2007, 10, 486.	0.9	0
105	Protein binding of cefazolin is saturable in vivo both between and within patients. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 753-757.	1.1	61
106	Synergistic Combinations of Anticonvulsant Agents: What Is the Evidence from Animal Experiments?. <i>Epilepsia</i> , 2007, 48, 412-434.	2.6	53
107	Clinical efficacy and safety of cefovecin in the treatment of canine pyoderma and wound infections. <i>Journal of Small Animal Practice</i> , 2007, 48, 378-386.	0.5	23
109	The clinical implications of ageing for rational drug therapy. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 183-199.	0.8	200
110	Uptake of amitriptyline and nortriptyline with liposomes, proteins, and serum: Implications for drug detoxification. <i>Journal of Colloid and Interface Science</i> , 2008, 319, 81-93.	5.0	25
111	Determining binding sites of drugs on human serum albumin using FIA-QCM. <i>Biosensors and Bioelectronics</i> , 2008, 24, 48-54.	5.3	34
112	Generation of a Set of Simple, Interpretable ADMET Rules of Thumb. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 817-834.	2.9	794

#	ARTICLE	IF	CITATIONS
113	Infusion of albumin attenuates changes in serum protein binding of drugs in surgical patients compared with volume replacement with HAES. <i>Acta Anaesthesiologica Scandinavica</i> , 2008, 52, 406-412.	0.7	11
114	Influence of acute normovolaemic haemodilution on bispectral index monitoring and propofol dose requirements. <i>Acta Anaesthesiologica Scandinavica</i> , 2008, 52, 815-820.	0.7	4
115	Therapeutic Drug Monitoring of Phenytoin in Critically Ill Patients. <i>Pharmacotherapy</i> , 2008, 28, 1391-1400.	1.2	73
116	A Review of Albumin Binding in CKD. <i>American Journal of Kidney Diseases</i> , 2008, 51, 839-850.	2.1	99
117	Free Drug Metabolic Clearance in Elderly People. <i>Clinical Pharmacokinetics</i> , 2008, 47, 297-321.	1.6	115
118	Pharmacokinetics and ADME optimization in drug discovery. , 2008, , 131-153.		3
119	Some features of the kinetics and equilibrium of drug binding to plasma proteins. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 1479-1498.	1.5	28
120	Impact of pH on Plasma Protein Binding in Equilibrium Dialysis. <i>Molecular Pharmaceutics</i> , 2008, 5, 438-448.	2.3	75
121	Applying Organ Clearance Concepts in a Clinical Setting. <i>American Journal of Pharmaceutical Education</i> , 2008, 72, 121.	0.7	5
122	All Dexâ€™med Out With Nowhere to Go?. <i>Journal of Clinical Oncology</i> , 2008, 26, 1917-1918.	0.8	0
123	Plasma Protein Binding. , 2008, , 187-196.		3
124	Local Kinetics and Dynamics of Xenobiotics. <i>Critical Reviews in Toxicology</i> , 2008, 38, 697-720.	1.9	38
125	Effects of Duloxetine on the Pharmacodynamics and Pharmacokinetics of Warfarin at Steady State in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 1456-1466.	1.0	21
126	Glucosamine Binding to Proteins in Plasma and Synovial Fluid and Blood Cell/Plasma Partitioning in Mouse and Man in Vitro. <i>Drug Metabolism and Drug Interactions</i> , 2009, 24, 211-27.	0.3	1
127	Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: Impact of plasma and microsomal binding. <i>Xenobiotica</i> , 2009, 39, 227-235.	0.5	36
128	Transport of Dicationic Drugs Pentamidine and Furamidine by Human Organic Cation Transporters. <i>Drug Metabolism and Disposition</i> , 2009, 37, 424-430.	1.7	76
129	Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 1223-1232.	1.3	25
130	Optimizing Pediatric Dosing: A Developmental Pharmacologic Approach. <i>Pharmacotherapy</i> , 2009, 29, 680-690.	1.2	119



#	ARTICLE	IF	CITATIONS
131	Effects of hepatic impairment on the pharmacokinetics of nilotinib: An open-label, single-dose, parallel-group study. <i>Clinical Therapeutics</i> , 2009, 31, 2459-2469.	1.1	31
132	Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. <i>Drug Discovery Today</i> , 2009, 14, 358-372.	3.2	101
133	Interindividual Pharmacokinetics Variability of the $\pm$ 4 $\beta$ 1 Integrin Antagonist, 4-[1-[3-Chloro-4-[(2-methylphenyl) ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl] methoxybenzoic Acid (D01-4582), in Beagles Is Associated with Albumin Genetic Polymorphisms. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 1545-1555.	1.6	11
134	Binding of Imipramine, Dosulepin, and Opipramol to Liposomes for Overdose Treatment. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 3718-3729.	1.6	7
135	Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2009, 36, 541-564.	0.8	73
136	Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of orbifloxacin in Korean Hanwoo cattle. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2009, 32, 219-228.	0.6	18
137	Irreversible CYP3A Inhibition Accompanied by Plasma Protein Binding Displacement: A Comparative Analysis in Subjects With Normal and Impaired Liver Function. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 319-326.	2.3	29
138	Drug Dosing in Patients With Impaired Renal Function. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 483-489.	2.3	49
139	Impact of plasma-protein binding on receptor occupancy: An analytical description. <i>Journal of Theoretical Biology</i> , 2009, 256, 253-262.	0.8	26
140	Protein Binding of Antimicrobials: Methods for Quantification and for Investigation of its Impact on Bacterial Killing. <i>AAPS Journal</i> , 2009, 11, 1-12.	2.2	56
141	Delayed Arousal. <i>Anesthesiology Clinics</i> , 2009, 27, 429-450.	0.6	6
142	Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. <i>Drug and Alcohol Dependence</i> , 2009, 101, 158-168.	1.6	67
143	A physiologically based pharmacokinetic model linking plasma protein binding interactions with drug disposition. <i>Research in Veterinary Science</i> , 2009, 86, 293-301.	0.9	25
145	Effect of Pregnancy on the Pharmacokinetics of Antihypertensive Drugs. <i>Clinical Pharmacokinetics</i> , 2009, 48, 159-168.	1.6	43
146	Pharmacokinetic and Pharmacodynamic Parameters of Antimicrobials. <i>Clinical Pharmacokinetics</i> , 2009, 48, 517-528.	1.6	38
147	Pharmacokinetic Modelling of the Plasma Protein Binding of Mycophenolic Acid in Renal Transplant Recipients. <i>Clinical Pharmacokinetics</i> , 2009, 48, 463-476.	1.6	35
149	Pharmacokinetics and drug metabolism in the elderly. <i>Drug Metabolism Reviews</i> , 2009, 41, 67-76.	1.5	614
150	Pediatric Palliative Care. <i>Paediatric Drugs</i> , 2009, 11, 129-151.	1.3	92

#	ARTICLE	IF	CITATIONS
151	Attenuating the effects of cardiac arrest on hepatic drug metabolism: Just chill out!*. Critical Care Medicine, 2009, 37, 369-370.	0.4	0
152	Valproic Acid Toxicity Associated With Low Dose of Aspirin and Low Total Valproic Acid Levels. Journal of Clinical Psychopharmacology, 2009, 29, 509-511.	0.7	11
154	Mass Spectrometry for In Vitro ADME Screening. , 2009, , 99-126.		0
155	Clinical Drug-Drug Interactions. , 0, , 535-546.		0
156	Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. Antiviral Therapy, 2010, 15, 817-829.	0.6	26
158	The older rheumatoid arthritis patients: who are they and how should they be treated?. Aging Health, 2010, 6, 533-549.	0.3	1
160	Dosing dilemmas in obese children. Archives of Disease in Childhood: Education and Practice Edition, 2010, 95, 112-117.	0.3	73
161	Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. Journal of Pharmacokinetics and Pharmacodynamics, 2010, 37, 3-24.	0.8	32
162	Developmental Pharmacokinetics. Seminars in Pediatric Neurology, 2010, 17, 208-213.	1.0	45
163	Optimising in vivo pharmacology studies-Practical PKPD considerations. Journal of Pharmacological and Toxicological Methods, 2010, 61, 146-156.	0.3	48
164	Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: An open-label, multiple-dose, controlled Phase I study in adults. Clinical Therapeutics, 2010, 32, 328-337.	1.1	19
166	Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics. Journal of Pharmaceutical Sciences, 2010, 99, 1107-1122.	1.6	267
167	On the influence of protein binding on pharmacological activity of drugs. Journal of Pharmaceutical Sciences, 2010, 99, 2153-2165.	1.6	37
168	A Physiologically Based Pharmacokinetic (PBPK) Model for Predicting the Efficacy of Drug Overdose Treatment With Liposomes in Man. Journal of Pharmaceutical Sciences, 2010, 99, 3601-3619.	1.6	17
169	Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. British Journal of Clinical Pharmacology, 2010, 70, 88-101.	1.1	12
170	The "apparent clearance"™ of free phenytoin in elderly <i>vs.</i> younger adults. British Journal of Clinical Pharmacology, 2010, 70, 132-138.	1.1	14
171	Patient variation in veterinary medicine: part I. Influence of altered physiological states. Journal of Veterinary Pharmacology and Therapeutics, 2010, 33, 213-226.	0.6	44
172	The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nature Reviews Drug Discovery, 2010, 9, 929-939.	21.5	695

#	ARTICLE	IF	CITATIONS
173	Influence of Alpha-1 Glycoprotein Acid Concentrations and Variants on Atazanavir Pharmacokinetics in HIV-Infected Patients Included in the ANRS 107 Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 614-619.	1.4	26
174	Pharmacokinetics and Bioavailability of Moxifloxacin in Calves following Different Routes of Administrations. <i>Chemotherapy</i> , 2010, 56, 26-31.	0.8	6
175	Do We Need Different Treatments for Very Elderly COPD Patients?. <i>Respiration</i> , 2010, 80, 357-368.	1.2	25
176	Symptomatic Hypoglycemia Associated with Trimethoprim/Sulfamethoxazole and Repaglinide in a Diabetic Patient. <i>Annals of Pharmacotherapy</i> , 2010, 44, 764-767.	0.9	25
177	Review on Pharmacokinetics and Pharmacodynamics and the Aging Kidney. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 314-327.	2.2	125
178	Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions. <i>Current Medicinal Chemistry</i> , 2010, 17, 571-584.	1.2	280
180	Discovery of <i>Omecamtiv Mecarbil</i> the First, Selective, Small Molecule Activator of Cardiac Myosin. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 472-477.	1.3	95
181	Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice. <i>Pharmacological Research</i> , 2010, 61, 385-390.	3.1	40
183	The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1215-1230.	1.5	11
184	Aminoglycoside modifying enzymes. <i>Drug Resistance Updates</i> , 2010, 13, 151-171.	6.5	1,007
185	Serum-protein effects on the detection of the $\beta_2$ -blocker propranolol by ion-transfer voltammetry at a micro-ITIES array. <i>Talanta</i> , 2010, 80, 1993-1998.	2.9	42
187	Geriatric drug therapy: Neglecting the inevitable majority. <i>Ageing Research Reviews</i> , 2010, 9, 384-398.	5.0	128
188	Protein Binding: Do We Ever Learn?. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3067-3074.	1.4	212
189	The "Tozer model of drug distribution and its suitability for drugs with different pharmacokinetic behavior. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1233-1243.	1.5	3
190	Pharmacokinetic drug-drug interactions with methotrexate in oncology. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 743-750.	1.3	50
191	Monitoring free drug concentrations: challenges. <i>Bioanalysis</i> , 2011, 3, 1753-1768.	0.6	51
192	Dried blood spots, pharmacokinetic studies and better medicines for children. <i>Bioanalysis</i> , 2011, 3, 779-786.	0.6	53
193	Effects of Nilotinib on Single-Dose Warfarin Pharmacokinetics and Pharmacodynamics. <i>Clinical Drug Investigation</i> , 2011, 31, 169-179.	1.1	23

#	ARTICLE	IF	CITATIONS
194	Duloxetine. <i>Clinical Pharmacokinetics</i> , 2011, 50, 281-294.	1.6	162
195	Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development. <i>Drug Metabolism and Drug Interactions</i> , 2011, 26, 147-68.	0.3	18
197	Plasma protein binding and blood-free concentrations: which studies are needed to develop a drug?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1009-1020.	1.5	27
198	<i>Pharmacology of Pediatric Anesthesia.</i> , 2011, , 179-261.		16
199	Clinical Pharmacokinetics of Triple Immunosuppression Scheme in Kidney Transplant (Tacrolimus,) Tj ETQq0 0 0 rgBT /Overloğk 10 Tf 50		
200	<i>Pharmacokinetics of opioids.</i> , 0, , 509-530.		2
201	<i>Geriatric pharmacology.</i> , 0, , 1139-1150.		0
202	Steric and Allosteric Effects of Fatty Acids on the Binding of Warfarin to Human Serum Albumin Revealed by Molecular Dynamics and Free Energy Calculations. <i>Chemical and Pharmaceutical Bulletin</i> , 2011, 59, 860-867.	0.6	32
203	Phenobarbital and some anesthesia implications. <i>Paediatric Anaesthesia</i> , 2011, 21, 995-997.	0.6	12
204	Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 52-60.	1.1	5
205	Riluzole pharmacokinetics in young patients with spinal muscular atrophy. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 403-410.	1.1	18
206	Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisal. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 758-767.	1.1	67
207	Population pharmacokinetics of mavacoxib in osteoarthritic dogs. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2011, 34, 1-11.	0.6	33
208	Competitive binding to plasma thyroid hormone transport proteins and thyroid disruption by phenylbutazone used as a probe. <i>General and Comparative Endocrinology</i> , 2011, 174, 225-231.	0.8	5
209	Use of unbound volumes of drug distribution in pharmacokinetic calculations. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 42, 91-98.	1.9	15
210	Gestational influences on the pharmacokinetics of gestagenic drugs: A combined in silico, in vitro and in vivo analysis. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 42, 318-331.	1.9	11
211	Digoxin Therapy in the Elderly: Pharmacokinetic Considerations in Nursing. <i>Geriatric Nursing</i> , 2011, 32, 263-269.	0.9	1
212	Différences graphiques dans les courbes de réponse de l'indice bispectral en fonction de la concentration de propofol estimée par anesthésie intraveineuse à objectif de concentration. <i>Canadian Journal of Anaesthesia</i> , 2011, 58, 364-370.	0.7	10

#	ARTICLE	IF	CITATIONS
214	Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 222-232.	1.1	61
215	The Effect of Critical Illness on Drug Distribution. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 2030-2036.	0.9	31
216	Pharmacokinetics and Safety of a Single Intravenous Dose of the Antibiotic Tigecycline in Patients With Cirrhosis. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 93-101.	1.0	28
217	Immune Activation Mediated Change in Alpha-1-Acid Glycoprotein: Impact on Total and Free Lopinavir Plasma Exposure. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1539-1548.	1.0	26
218	Influence of Severe Renal Impairment on the Pharmacokinetics of Clazosentan. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 413-421.	1.0	7
219	Population pharmacokinetic analysis of ropivacaine and its metabolite 2,6-pipecoloxylidide from pooled data in neonates, infants, and children. <i>British Journal of Anaesthesia</i> , 2011, 107, 409-424.	1.5	39
220	Drug interactions in metastatic breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2011, 17, 236-245.	0.5	2
221	Control and Measurement of Plasma pH in Equilibrium Dialysis: Influence on Drug Plasma Protein Binding. <i>Drug Metabolism and Disposition</i> , 2011, 39, 551-557.	1.7	35
222	Effect of age on the pharmacokinetics of fimasartan (BR-A-657). <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1337-1344.	1.5	21
223	Pharmacokinetic and Pharmacodynamic Variability of Fluindione in Octogenarians. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 777-786.	2.3	7
224	The Increased Cellular Uptake and Biliary Excretion of Curcumin by Quercetin: A Possible Role of Albumin Binding Interaction. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1452-1455.	1.7	24
225	Clinical Pharmacology in Old Persons. <i>Scientifica</i> , 2012, 2012, 1-17.	0.6	41
227	Telaprevir: Pharmacokinetics and Drug Interactions. <i>Antiviral Therapy</i> , 2012, 17, 1211-1221.	0.6	41
228	Bioavailability Challenges Associated with Development of Saponins As Therapeutic and Chemopreventive Agents. <i>Current Drug Targets</i> , 2012, 13, 1885-1899.	1.0	52
229	Introduction to Drug Pharmacokinetics in the Critically Ill Patient. <i>Chest</i> , 2012, 141, 1327-1336.	0.4	199
230	Interactions and Monitoring of Antipsychotic Drugs. <i>Handbook of Experimental Pharmacology</i> , 2012, , 241-265.	0.9	19
231	Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 515-524.	1.1	25
232	Population Pharmacokinetics of Unbound Mycophenolic Acid in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1665-1675.	1.0	22

#	ARTICLE	IF	CITATIONS
233	Clinical Pharmacokinetics and Pharmacodynamics of Prednisolone and Prednisone in Solid Organ Transplantation. <i>Clinical Pharmacokinetics</i> , 2012, 51, 711-741.	1.6	92
234	Heterocyclic methylsulfone hydroxamic acid LpxC inhibitors as Gram-negative antibacterial agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6832-6838.	1.0	33
235	Human serum albumin: From bench to bedside. <i>Molecular Aspects of Medicine</i> , 2012, 33, 209-290.	2.7	1,320
237	Drug Therapy in the Elderly. , 2012, , 437-453.		1
238	Calculation of Normalized Drug Concentrations in the Presence of Altered Plasma Protein Binding. <i>Clinical Pharmacokinetics</i> , 2012, 51, 55-68.	1.6	28
239	Clinical Pharmacokinetics of Fingolimod. <i>Clinical Pharmacokinetics</i> , 2012, 51, 15-28.	1.6	95
241	CHAPTER 17. Crossing the Blood-brain Barrier – Methods for Evaluating CNS Exposure. <i>RSC Drug Discovery Series</i> , 2012, , 445-464.	0.2	1
243	Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1662-1670.	2.9	90
246	Methods for Assessing Blood-Brain Barrier Penetration in Drug Discovery. , 2012, , 169-175.		3
248	Potent Inhibitors of LpxC for the Treatment of Gram-Negative Infections. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 914-923.	2.9	100
249	Implications of Plasma Protein Binding for Pharmacokinetics and Pharmacodynamics of the $\beta$ -Secretase Inhibitor RO4929097. <i>Clinical Cancer Research</i> , 2012, 18, 2066-2079.	3.2	22
250	Clinical pharmacology of nonsteroidal anti-inflammatory drugs in dogs. <i>Veterinary Anaesthesia and Analgesia</i> , 2012, 39, 69-90.	0.3	133
251	Compilation of 222 drugs' plasma protein binding data and guidance for study designs. <i>Drug Discovery Today</i> , 2012, 17, 475-485.	3.2	172
252	Prescribing medicines for older patients. <i>Medicine</i> , 2012, 40, 382-385.	0.2	2
253	Clinical impact of serum proteins on drug delivery. <i>Journal of Controlled Release</i> , 2012, 161, 429-445.	4.8	319
255	When is Protein Binding Important?*. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3458-3467.	1.6	64
256	Diabetes and hypertension increase the placental and transcellular permeation of the lipophilic drug diazepam in pregnant women. <i>BMC Pregnancy and Childbirth</i> , 2013, 13, 188.	0.9	6
257	Increasing Extracellular Protein Concentration Reduces Intracellular Antiretroviral Drug Concentration and Antiviral Effect. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1434-1442.	0.5	14

#	ARTICLE	IF	CITATIONS
258	The Clinical Relevance of Plasma Protein Binding Changes. <i>Clinical Pharmacokinetics</i> , 2013, 52, 1-8.	1.6	225
259	Synthesis of acylated glycoconjugates as templates to investigate in vitro biopharmaceutical properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 455-459.	1.0	23
260	Disposition of ON 01210.Na (Ex-RAD(R)), a Novel Radioprotectant, in the Isolated Perfused Rat Liver: Probing Metabolic Inhibition to Increase Systemic Exposure. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 732-740.	1.6	2
261	Faster non-renal clearance of metoprolol in streptozotocin-induced diabetes mellitus rats. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 50, 447-453.	1.9	4
262	Drug absorption, distribution, metabolism and excretion considerations in critically ill adults. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1067-1084.	1.5	72
263	The bioanalytical challenge of determining unbound concentration and protein binding for drugs. <i>Bioanalysis</i> , 2013, 5, 3033-3050.	0.6	58
264	The fish tank model of first-order elimination: An effective pharmacokinetic teaching tool. <i>Currents in Pharmacy Teaching and Learning</i> , 2013, 5, 402-409.	0.4	0
265	Study on the plasma protein binding rate of Schisandra lignans based on the LC-IT-TOF/MS technique with relative quantitative analysis. <i>Chinese Journal of Natural Medicines</i> , 2013, 11, 442-448.	0.7	9
266	Correspondence of Fatty Acid and Drug Binding Sites on Human Serum Albumin: A Two-Dimensional Nuclear Magnetic Resonance Study. <i>Biochemistry</i> , 2013, 52, 1559-1567.	1.2	71
268	Distribution - In Vitro Tests - Protein Binding. , 2013, , 897-913.		2
269	On the Accuracy of a One-Compartment Approach for Determination of Drug Terminal Half-Life. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 2082-2084.	1.6	3
270	Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin. <i>Epilepsia</i> , 2013, 54, 1161-1166.	2.6	25
271	<i>in silico</i> prediction of human serum albumin binding for drug leads. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 583-595.	2.5	36
272	Plasma protein binding: From discovery to development. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 2953-2994.	1.6	279
273	Demystifying Brain Penetration in Central Nervous System Drug Discovery. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2-12.	2.9	243
274	Pharmacokinetic Interaction between Telaprevir and Methadone. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2304-2309.	1.4	27
275	Silibinin hemisuccinate binding to proteins in plasma and blood cell/plasma partitioning in mouse, rat, dog and man <i>in vitro</i> . <i>Drug Metabolism and Drug Interactions</i> , 2013, 28, 115-122.	0.3	3
276	Pharmacokinetics of drugs in mutant Nagase analbuminemic rats and responses to select diuretics. <i>Journal of Pharmacy and Pharmacology</i> , 2013, 66, 2-13.	1.2	1



#	ARTICLE	IF	CITATIONS
277	Characterization of Binding of Raltegravir to Plasma Proteins. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5147-5150.	1.4	17
278	Numerous protein-bound solutes are cleared by the kidney with high efficiency. <i>Kidney International</i> , 2013, 84, 585-590.	2.6	111
279	Importance of Relating Efficacy Measures to Unbound Drug Concentrations for Anti-Infective Agents. <i>Clinical Microbiology Reviews</i> , 2013, 26, 274-288.	5.7	121
280	Geriatric clinical pharmacology and clinical trials in the elderly. <i>Translational and Clinical Pharmacology</i> , 2014, 22, 64.	0.3	6
281	Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients. <i>Kidney International</i> , 2014, 85, 1434-1443.	2.6	38
282	Complex Diseaseâ€™, Geneâ€™, and Drugâ€™Drug Interactions: Impacts of Renal Function, CYP2D6 Phenotype, and OCT2 Activity on Veliparib Pharmacokinetics. <i>Clinical Cancer Research</i> , 2014, 20, 3931-3944.	3.2	29
283	Visualization of Plasma and Tissue Binding Using Dose Fractions Parameter. <i>Drug Development Research</i> , 2014, 75, 425-437.	1.4	5
285	Induction of liver cytochrome P450s by Danshenâ€™Gegen formula is the leading cause for its pharmacokinetic interactions with warfarin. <i>Journal of Ethnopharmacology</i> , 2014, 154, 672-686.	2.0	21
286	Pharmacokinetics of drugs in spontaneously or secondary hypertensive rats. <i>Xenobiotica</i> , 2014, 44, 77-88.	0.5	1
287	Singleâ€™dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 732-741.	1.0	26
288	Equilibrium Gel Filtration to Measure Plasma Protein Binding of Very Highly Bound Drugs. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 752-759.	1.6	13
289	Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 409-419.	0.8	5
290	Consideration of the Unbound Drug Concentration in Enzyme Kinetics. <i>Methods in Molecular Biology</i> , 2014, 1113, 119-145.	0.4	5
291	Effect of Ritonavirâ€™Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on the Pharmacokinetics of Methadone in Healthy Subjects Undergoing Methadone Maintenance Therapy. <i>Pharmacotherapy</i> , 2014, 34, 220-226.	1.2	3
292	Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 775-789.	0.8	8
293	Pharmacokinetic of Antiepileptic Drugs in Patients with Hepatic or Renal Impairment. <i>Clinical Pharmacokinetics</i> , 2014, 53, 29-49.	1.6	26
294	Drugâ€™drug interactions with tyrosine-kinase inhibitors: a clinical perspective. <i>Lancet Oncology</i> , The, 2014, 15, e315-e326.	5.1	205
295	Rational Use of Plasma Protein and Tissue Binding Data in Drug Design. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 8238-8248.	2.9	135



#	ARTICLE	IF	CITATIONS
296	Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 95-115.	1.1	26
297	<i>In Vitro</i> Activity and Resistance Profile of Samatasvir, a Novel NS5A Replication Inhibitor of Hepatitis C Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4431-4442.	1.4	28
298	Clinical Pharmacology of Deferasirox. <i>Clinical Pharmacokinetics</i> , 2014, 53, 679-694.	1.6	33
299	Analysis of Binding Interaction Between Antibacterial Ciprofloxacin and Human Serum Albumin by Spectroscopic Techniques. <i>Cell Biochemistry and Biophysics</i> , 2014, 70, 93-101.	0.9	48
300	Integrated Population Pharmacokinetic/Viral Dynamic Modelling of Lopinavir/Ritonavir in HIV-1 Treatment-Naïve Patients. <i>Clinical Pharmacokinetics</i> , 2014, 53, 361-371.	1.6	13
301	Sex Differences in the Pharmacokinetics of Antidepressants: Influence of Female Sex Hormones and Oral Contraceptives. <i>Clinical Pharmacokinetics</i> , 2014, 53, 509-519.	1.6	57
303	Drug-drug interactions with tyrosine-kinase inhibitors. <i>Lancet Oncology</i> , The, 2014, 15, e416.	5.1	2
304	Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: Additional supportive evidence. <i>Epilepsy Research</i> , 2014, 108, 725-731.	0.8	43
305	Consequences of Renal Failure on Non-Renal Clearance of Drugs. <i>Clinical Pharmacokinetics</i> , 2014, 53, 521-532.	1.6	43
307	A simple introduction to pharmacokinetics: Part 1. <i>NursePrescribing</i> , 2014, 12, 497-503.	0.1	4
308	Plasma Protein Binding of Challenging Compounds. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 2627-2636.	1.6	78
309	2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 1) Tj ETQq1_1_0.784314 rgBT 0.6 35	1.1	1
310	Pharmacokinetic changes of drugs in a rat model of liver cirrhosis induced by dimethylnitrosamine, alone and in combination with diabetes mellitus induced by streptozotocin. <i>Biopharmaceutics and Drug Disposition</i> , 2015, 36, 1-14.	1.1	1
311	Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 362-371.	1.3	15
313	Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 76-86.	2.3	45
314	The pharmacokinetics and safety of darapladib in subjects with severe renal impairment. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 654-661.	1.1	2
315	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 510-514.	0.9	6
316	Lack of drug interaction between cyclosporine and telaprevir in a liver transplant recipient. <i>Transplant Infectious Disease</i> , 2015, 17, 106-110.	0.7	0

#	ARTICLE	IF	CITATIONS
317	Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1031-1041.	1.1	51
318	Antiepileptic drugs alter the expression of placental carriers: An in vitro study in a human placental cell line. <i>Epilepsia</i> , 2015, 56, 1023-1032.	2.6	42
319	Study on the interaction of plasma protein binding rate between edaravone and taurine in human plasma based on HPLC analysis coupled with ultrafiltration technique. <i>Biomedical Chromatography</i> , 2015, 29, 1137-1145.	0.8	10
320	A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD. <i>Seminars in Dialysis</i> , 2015, 28, 325-329.	0.7	30
321	Association between use of warfarin with common sulfonylureas and serious hypoglycemic events: retrospective cohort analysis. <i>BMJ, The</i> , 2015, 351, h6223.	3.0	30
323	Challenges in Pharmacology Modelling. <i>Journal of Dynamics and Differential Equations</i> , 2015, 27, 941-959.	1.0	1
324	Anesthetic Management During Cardiopulmonary Bypass. <i>Anesthesia and Analgesia</i> , 2015, 120, 749-769.	1.1	72
325	Semi-Mechanism-Based Population Pharmacokinetic Modeling of the Hedgehog Pathway Inhibitor Vismodegib. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 680-689.	1.3	17
326	The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. <i>Epilepsia</i> , 2015, 56, 12-27.	2.6	224
327	Gender differences in corydaline pharmacokinetics in rats. <i>Xenobiotica</i> , 2015, 45, 456-463.	0.5	10
329	Alterations in drug disposition in older adults. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 491-508.	1.5	91
330	Simple Method Provides Resolution of Albumin, Lipoprotein, Free Fraction, and Chylomicron To Enhance the Utility of Protein Binding Assays. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1420-1425.	2.9	9
331	Drug-Drug Interactions Related to Altered Absorption and Plasma Protein Binding: Theoretical and Regulatory Considerations, and an Industry Perspective. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 916-929.	1.6	21
332	Investigation of the prerequisites for the optimization of specific plasma protein binding as a strategy for the reduction of first-pass hepatic metabolism. <i>Xenobiotica</i> , 2015, 45, 286-301.	0.5	3
333	Geriatric Pharmacology. <i>Anesthesiology Clinics</i> , 2015, 33, 457-469.	0.6	16
334	Short-Term Fasting Alters Cytochrome P450-Mediated Drug Metabolism in Humans. <i>Drug Metabolism and Disposition</i> , 2015, 43, 819-828.	1.7	26
335	Exposure to Total and Protein-Unbound Rifampin Is Not Affected by Malnutrition in Indonesian Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3233-3239.	1.4	22
336	In vitro, in silico and integrated strategies for the estimation of plasma protein binding. A review. <i>Advanced Drug Delivery Reviews</i> , 2015, 86, 27-45.	6.6	92

#	ARTICLE	IF	CITATIONS
337	Pharmacokinetic considerations for drugs administered in the critically ill. <i>British Journal of Hospital Medicine</i> (London, England: 2005), 2015, 76, 89-94.	0.2	6
338	Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 525-533.	1.1	80
339	Population Approach To Analyze the Pharmacokinetics of Free and Total Lopinavir in HIV-Infected Pregnant Women and Consequences for Dose Adjustment. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5727-5735.	1.4	12
340	Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor " Teneligliptin in rats using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2015, 1002, 194-200.	1.2	19
341	Pharmacologic studies in vulnerable populations: Using the pediatric experience. <i>Seminars in Perinatology</i> , 2015, 39, 532-536.	1.1	22
342	The impact of drug interactions and polypharmacy on antimicrobial therapy in the elderly. <i>Clinical Microbiology and Infection</i> , 2015, 21, 20-26.	2.8	43
343	Population pharmacokinetics of phenytoin in critically ill children. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 355-364.	1.0	9
344	Effects of capsaicin on pharmacokinetics of pitavastatin in rats. <i>Xenobiotica</i> , 2015, 45, 171-176.	0.5	7
345	Therapeutic Drug Monitoring in Older People. , 2016, , 213-229.		0
346	Plasma and Tissue Binding. , 2016, , 219-228.		1
347	Quinine Unbound Concentration Has to Be Used for Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 556-557.	1.0	3
348	Antibiothérapie du sujet âgé : On peut toujours mieux faire. <i>Canadian Journal on Aging</i> , 2016, 35, 385-392.	0.6	0
349	When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1934-1939.	1.7	35
350	Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 625-635.	1.3	50
352	Quinine unbound concentration is the best marker for therapeutic drug monitoring. <i>Therapie</i> , 2016, 71, 487-489.	0.6	1
353	Mechanism of Drug-Drug Interactions Between Warfarin and Statins. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 1976-1986.	1.6	34
354	Clinically Significant Interactions with Antipsychotics. , 2016, , 397-421.		2
355	Principi di farmacocinetica applicati all'anestesia. <i>EMC - Anestesia-Rianimazione</i> , 2016, 21, 1-14.	0.1	0

#	ARTICLE	IF	CITATIONS
356	Prevalence and Implications of Abnormal Laboratory Results in Patients in the Terminal Phase of Life. <i>Journal of Palliative Medicine</i> , 2016, 19, 822-829.	0.6	8
357	Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin. <i>Annals of Pharmacotherapy</i> , 2016, 50, 909-917.	0.9	27
358	Dual Action Enhancement of Gold Nanoparticle Radiosensitization by Pentamidine in Triple Negative Breast Cancer. <i>Radiation Research</i> , 2016, 185, 549.	0.7	29
359	Pharmacokinetic and pharmacodynamic changes in older adults and implications for palliative care. <i>Progress in Palliative Care</i> , 2016, 24, 255-261.	0.7	5
360	Effect of acute hypervolemic hemodilution of 6% hydroxyethyl starch 130/0.4 on the EC50 of propofol at two clinical endpoints in patients. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 110-116.	0.8	6
361	Principios de farmacocinética aplicados a la anestesia. <i>EMC - Anestesia-Reanimación</i> , 2016, 42, 1-15.	0.1	1
362	Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 682-691.	1.3	54
363	Age and the Process of Aging. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2016, , 67-86.	0.2	2
364	Population pharmacokinetic analysis to recommend the optimal dose of udenafil in patients with mild and moderate hepatic impairment. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 389-398.	1.1	2
365	Mathematical modeling and simulation in animal health. Part I: Moving beyond pharmacokinetics. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2016, 39, 213-223.	0.6	28
366	Prescribing medicines for older patients. <i>Medicine</i> , 2016, 44, 433-437.	0.2	3
367	Blood-Brain Barrier. , 2016, , 141-159.		2
368	Exploration of PBPK Model Calculation of Drug Time Course in Tissue Using IV Bolus Drug Plasma Concentration-Time Profile and the Physiological Parameters of the Organ. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 2453-2458.	1.6	2
369	The impact of medetomidine on the protein-binding characteristics of MK-467 in canine plasma. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2016, 39, 405-407.	0.6	3
370	Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 369-379.	1.1	25
371	Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure. <i>Pharmaceutical Research</i> , 2016, 33, 269-282.	1.7	31
373	Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2016, 26, 314-326.	0.7	59
374	Variations of pharmacokinetics of drugs in patients with cirrhosis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 441-458.	1.3	17

#	ARTICLE	IF	CITATIONS
375	The impact of the concentration of drug binding plasma proteins on drug distribution according to Åie-Tozerâ€™s model. <i>Xenobiotica</i> , 2016, 46, 307-314.	0.5	4
376	Glycation alter serum albumin binding of valsartan and nateglinide when studied contemporarily. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2017, 40, 26-35.	0.5	2
377	Effect of Short-Term Fasting on Systemic Cytochrome P450-Mediated Drug Metabolism in Healthy Subjects: A Randomized, Controlled, Crossover Study Using a Cocktail Approach. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1231-1244.	1.6	18
378	Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 903-914.	0.6	47
379	Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. <i>Clinical Pharmacokinetics</i> , 2017, 56, 893-913.	1.6	639
380	Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1701-1712.	1.1	23
381	Old and new oral anticoagulants: Food, herbal medicines and drug interactions. <i>Blood Reviews</i> , 2017, 31, 193-203.	2.8	174
382	Systematic overdosing of oxa- and cloxacillin in severe infections treated in ICU: risk factors and side effects. <i>Annals of Intensive Care</i> , 2017, 7, 34.	2.2	22
383	Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers. <i>Clinical Drug Investigation</i> , 2017, 37, 303-309.	1.1	40
384	Pharmacologic Considerations of Anesthetic Agents in Geriatric Patients. <i>Anesthesiology Clinics</i> , 2017, 35, 259-271.	0.6	17
385	Pharmacokinetic and pharmacodynamic interactions in anaesthesia. A review of current knowledge and how it can be used to optimize anaesthetic drug administration. <i>British Journal of Anaesthesia</i> , 2017, 118, 44-57.	1.5	52
386	Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIVâ€™Infected Subjects With Aging Biomarkers. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 128-135.	1.3	7
387	A Review of Foodâ€™Drug Interactions on Oral Drug Absorption. <i>Drugs</i> , 2017, 77, 1833-1855.	4.9	116
388	Industry Perspective on Contemporary Protein-Binding Methodologies: Considerations for Regulatory Drug-Drug Interaction and Related Guidelines on Highly Bound Drugs. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 3442-3452.	1.6	69
389	Effects of serum albumin on SPR-measured affinity of small molecule inhibitors binding to nerve growth factor. <i>Sensing and Bio-Sensing Research</i> , 2017, 15, 1-4.	2.2	2
390	Clinical pharmacokinetics of methotrexate in oncology. <i>International Journal of Pharmacokinetics</i> , 2017, 2, 137-147.	0.5	21
391	Free Testosterone: Pumping up the Tires or Ending the Free Ride?. <i>Endocrine Reviews</i> , 2017, 38, 297-301.	8.9	48
392	Direct acting anti-hepatitis C virus drugs: Clinical pharmacology and future direction. <i>Journal of Translational Internal Medicine</i> , 2017, 5, 8-17.	1.0	120

#	ARTICLE	IF	CITATIONS
393	Lipophilicity Influences Drug Binding to $\alpha$ 1-Acid Glycoprotein F1/S Variants But Not to the A Variant. <i>Drugs in R and D</i> , 2017, 17, 475-480.	1.1	7
394	Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 269-293.	1.1	62
395	Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 181-189.	1.3	46
396	Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant. <i>Thrombosis and Haemostasis</i> , 2017, 117, 706-717.	1.8	11
397	Pharmacologic Therapies IV. , 2017, , 366-379.e5.		7
398	Drug Classification and Drug Disposition Prediction. , 2017, , 102-129.		0
399	Warfarin and Flavonoids Do Not Share the Same Binding Region in Binding to the IIA Subdomain of Human Serum Albumin. <i>Molecules</i> , 2017, 22, 1153.	1.7	36
400	Multiobjective Optimization of Biological and Physical Properties in Drug Discovery. , 2017, , 64-93.		0
401	Disease-Drug Interactions in Inflammatory States via Effects on CYP-Mediated Drug Clearance. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 849-863.	1.0	43
402	Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 140-146.	1.1	5
403	The Educated Guess. <i>Veterinary Clinics of North America - Exotic Animal Practice</i> , 2018, 21, 183-194.	0.4	4
404	Predicting Pharmacokinetics/Pharmacodynamics in the Individual Patient: Separating Reality From Hype. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 979-989.	1.0	7
405	Nonlinear Protein Binding: Not What You Think. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1754-1760.	1.6	20
406	Pharmacologic Principles. , 2018, , 79-137.		18
407	Ex vivo binding of the immunosuppressant mycophenolic acid to dog and cat plasma proteins and the effect of co-incubated dexamethasone and prednisolone. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2018, 41, 513-521.	0.6	4
408	A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 793-803.	0.8	10
409	A Physiologically Based Pharmacokinetic Perspective on the Clinical Utility of Albumin-Based Dose Adjustments in Critically Ill Patients. <i>Clinical Pharmacokinetics</i> , 2018, 57, 59-69.	1.6	7
410	In vivo potency revisited - Keep the target in sight. , 2018, 184, 177-188.		24

#	ARTICLE	IF	CITATIONS
411	Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 251-257.	0.6	8
412	Food-drug interactions involving multiple mechanisms: A case study with effect of Capsaicin on the pharmacokinetics of Irinotecan and its main metabolites in rat. <i>Journal of Functional Foods</i> , 2018, 40, 292-298.	1.6	4
413	Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults. <i>Clinical Pharmacokinetics</i> , 2018, 57, 515-527.	1.6	15
414	Improving Pediatric Protein Binding Estimates: An Evaluation of $\hat{\pm}1$ -Acid Glycoprotein Maturation in Healthy and Infected Subjects. <i>Clinical Pharmacokinetics</i> , 2018, 57, 577-589.	1.6	26
415	Effects of Plasma Albumin on the Pharmacokinetics of Esomeprazole in ICU Patients. <i>BioMed Research International</i> , 2018, 2018, 1-6.	0.9	5
416	QUANTITATIVE STRUCTURE-PHARMACOKINETICS RELATIONSHIP FOR PLASMA PROTEIN BINDING OF NEUTRAL DRUGS. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 2018, 10, 88.	0.3	1
417	Expert Evaluation of Preclinical Toxicokinetic Studies of Pharmaceuticals (Review). <i>Pharmaceutical Chemistry Journal</i> , 2018, 52, 753-757.	0.3	2
418	Food Bioactive Compounds and Their Interference in Drug Pharmacokinetic/Pharmacodynamic Profiles. <i>Pharmaceutics</i> , 2018, 10, 277.	2.0	45
419	Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 117-125.	1.3	17
420	A Strategy to Refine the Phenotyping Approach and Its Implementation to Predict Drug Clearance: A Physiologically Based Pharmacokinetic Simulation Study. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 798-808.	1.3	4
421	Pharmacokinetic Studies of Baclofen Are Not Sufficient to Establish an Optimized Dosage for Management of Alcohol Disorder. <i>Frontiers in Psychiatry</i> , 2018, 9, 485.	1.3	12
422	Testing for drug-human serum albumin binding using fluorescent probes and other methods. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 1005-1014.	2.5	17
424	Effect of age on plasma protein binding of several veterinary drugs in dairy calves 2. <i>Research in Veterinary Science</i> , 2018, 121, 59-64.	0.9	9
425	The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses. <i>Pharmaceutical Research</i> , 2018, 35, 242.	1.7	19
426	Challenges and innovations of drug delivery in older age. <i>Advanced Drug Delivery Reviews</i> , 2018, 135, 3-38.	6.6	39
427	Drug-Drug Interactions and Psychiatric Medication. , 2018, , 181-200.		0
428	Pharmacokinetics of pericyte involvement in small-molecular drug transport across the blood-brain barrier. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 122, 77-84.	1.9	8
430	Concentration-dependent plasma protein binding: Expect the unexpected. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 122, 341-346.	1.9	23



#	ARTICLE	IF	CITATIONS
431	In Vitro/In Vivo Correlation for Drug-Drug Interactions. , 2018, , 1-20.		0
432	Nutritional Status Differentially Alters Cytochrome P450 3A4 (CYP3A4) and Uridine 5- $\alpha$ -Diphospho-Glucuronosyltransferase (UGT) Mediated Drug Metabolism: Effect of Short-Term Fasting and High Fat Diet on Midazolam Metabolism. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 751-767.	0.6	7
433	Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps. Clinical Pharmacokinetics, 2019, 58, 309-323.	1.6	41
434	The effect of elevated $\alpha$ -acid glycoprotein on the pharmacokinetics of TAK-272 (SCO-272), an orally active renin inhibitor, in rats. Xenobiotica, 2019, 49, 584-590.	0.5	3
435	Pharmacokinetics and Pharmacology of Drugs Used in Children. , 2019, , 100-176.e45.		5
436	Four Decades of $\beta$ -Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis. Clinical Pharmacokinetics, 2019, 58, 143-156.	1.6	15
437	Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PMO1183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer. Clinical Pharmacokinetics, 2019, 58, 363-374.	1.6	18
439	Minimal impact of hepatic and renal impairment on plasma protein binding of lenvatinib, and identification of its major plasma binding protein. Biopharmaceutics and Drug Disposition, 2019, 40, 307-311.	1.1	4
440	Medications in Space: In Search of a Pharmacologist's Guide to the Galaxy. Pharmaceutical Research, 2019, 36, 148.	1.7	33
441	Absence of Pharmacokinetic Interactions between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 202-207.	1.3	4
443	Clinical Significance of the Plasma Protein Binding of Rifampicin in the Treatment of Tuberculosis Patients. Clinical Pharmacokinetics, 2019, 58, 1511-1515.	1.6	3
444	Pharmacokinetics and Pharmacodynamics of Antibiotics in Transplant Patients. , 2019, , 903-925.		0
445	Geriatric Pharmacology. Anesthesiology Clinics, 2019, 37, 475-492.	0.6	47
446	Risk Factors for Poor Pain Control after Opioid Switching from Oxycodone Tablet to Fentanyl Patch. Biological and Pharmaceutical Bulletin, 2019, 42, 1674-1678.	0.6	0
447	Development and Evaluation of Physiologically Based Pharmacokinetic Drug-Disease Models for Predicting Rifampicin Exposure in Tuberculosis and Cirrhosis Populations. Pharmaceutics, 2019, 11, 578.	2.0	17
448	Decreased warfarin sensitivity among patients treated with elbasvir and grazoprevir for hepatitis C infection. American Journal of Health-System Pharmacy, 2019, 76, 1273-1280.	0.5	3
450	Antitumor pharmacotherapy of colorectal cancer in kidney transplant recipients. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987619.	1.4	0
451	Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 3. Journal of Psychiatric Practice, 2019, 25, 34-40.	0.3	8



#	ARTICLE	IF	CITATIONS
452	Strategies to optimize drug half-life in lead candidate identification. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 221-230.	2.5	14
455	Impact of bovine respiratory disease on the pharmacokinetics of danofloxacin and tulathromycin in different ages of calves. <i>PLoS ONE</i> , 2019, 14, e0218864.	1.1	13
456	Optimal Dosing Regimen of Phenytoin for Korean Epilepsy Patients: From Premature Babies to the Elderly. <i>Journal of Pharmaceutical Sciences</i> , 2019, 108, 2765-2773.	1.6	3
457	Pharmacokinetics of Lapatinib, a Nonrenally Cleared Drug, in Patients With End-Stage Renal Disease on Maintenance Hemodialysis. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1379-1383.	1.0	4
458	Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma. <i>Clinical Pharmacokinetics</i> , 2019, 58, 983-1014.	1.6	17
459	Pharmacotherapy options and drug development in managing periprosthetic joint infections in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1109-1121.	0.9	4
460	Special Populations: Protein Binding Aspects. , 2019, , 1-8.		0
462	Personalized medicine: going to the dogs?. <i>Human Genetics</i> , 2019, 138, 467-481.	1.8	23
463	Understanding drug-drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 155-163.	0.8	21
464	Intracellular and Intraorgan Concentrations of Small Molecule Drugs: Theory, Uncertainties in Infectious Diseases and Oncology, and Promise. <i>Drug Metabolism and Disposition</i> , 2019, 47, 665-672.	1.7	31
465	Reassessing the dosing of cefoxitin prophylaxis during major abdominal surgery: insights from microdialysis and population pharmacokinetic modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1975-1983.	1.3	8
466	Optimization of the treatment with beta-lactam antibiotics in critically ill patients" guidelines from the French Society of Pharmacology and Therapeutics (Soci�t� Fran�saise de Pharmacologie et Tj ETQq1 1 0.784314 rgBT /Overlo	2.5	299
467	Effects of Orotic Acid-Induced Non-Alcoholic Fatty Liver on the Pharmacokinetics of Metoprolol and its Metabolites in Rats. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2019, 22, 98-111.	0.9	8
469	Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention. <i>Transplantation</i> , 2019, 103, 2012-2030.	0.5	43
470	Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1122-1135.	1.7	79
471	Potential protein-binding displacement interactions with perampanel: An in vitro analysis. <i>Epilepsy Research</i> , 2019, 149, 102-106.	0.8	10
472	Evaluation of a Potential Clinical Significant Drug-Drug Interaction between Digoxin and Bupropion in Cynomolgus Monkeys. <i>Pharmaceutical Research</i> , 2019, 36, 1.	1.7	37
473	Quantitative Assessment of the Effect of Chronic Kidney Disease on the Nonrenal Clearance of 10 Drugs After Intravenous Administration. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 138-151.	0.8	0

#	ARTICLE	IF	CITATIONS
474	Interaction between warfarin and cannabis. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2019, 124, 28-31.	1.2	68
475	Clearance in Drug Design. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2245-2255.	2.9	99
476	Pharmacokinetic alterations in poloxamer 407-induced hyperlipidemic rats. <i>Xenobiotica</i> , 2019, 49, 611-625.	0.5	7
477	Pharmacokinetics in children with chronic kidney disease. <i>Pediatric Nephrology</i> , 2020, 35, 1153-1172.	0.9	12
478	The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 639-650.	0.8	17
479	A summary of the current drug interaction guidance from the European Medicines Agency and considerations of future updates. <i>Drug Metabolism and Pharmacokinetics</i> , 2020, 35, 2-11.	1.1	12
480	Clinically relevant drug interactions between newer antidepressants and oral anticoagulants. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 31-44.	1.5	27
481	Unbound Vitamin D Concentrations Are Not Decreased in Critically Ill Patients. <i>Internal Medicine Journal</i> , 2020, , .	0.5	5
482	Pharmacokinetic Variability During Long-Term Therapeutic Drug Monitoring of Valproate, Clobazam, and Levetiracetam in Patients With Dravet Syndrome. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 744-753.	1.0	6
483	Prevalence and risk factors of baclofen neurotoxicity in patients with severely impaired renal function. <i>Nefrologia</i> , 2020, 40, 543-551.	0.2	3
485	Perioperative pharmacokinetics and pharmacodynamics of meloxicam in emus ( <i>Dromaius</i> ) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 347 <i>Veterinary Pharmacology and Therapeutics</i> , 2021, 44, 603-618.	0.6	8
486	Indomethacin Increases Quercetin Affinity for Human Serum Albumin: A Combined Experimental and Computational Study and Its Broader Implications. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5740.	1.8	6
487	Updated pharmacokinetic considerations for the use of antimalarial drugs in pregnant women. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 741-758.	1.5	3
488	Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 64-68.	2.3	21
490	Drug-Drug Interactions of 257 Antineoplastic and Supportive Care Agents With 7 Anticoagulants: A Comprehensive Review of Interactions and Mechanisms. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962093632.	0.7	17
491	A Physiologically Based Pharmacokinetic Model of Vismodegib: Deconvoluting the Impact of Saturable Plasma Protein Binding, pH-Dependent Solubility and Nonsink Permeation. <i>AAPS Journal</i> , 2020, 22, 117.	2.2	9
492	Potential statin drug interactions in elderly patients: a review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 1133-1145.	1.5	17
493	Drug-Drug Interaction Studies With Oral Contraceptives: Pharmacokinetic/Pharmacodynamic and Study Design Considerations. <i>Journal of Clinical Pharmacology</i> , 2020, 60, S49-S62.	1.0	11

#	ARTICLE	IF	CITATIONS
494	Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against <i>Enterobacteriaceae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	6
495	Comparative Plasma Pharmacokinetics of Ceftriaxone and Ertapenem in Normoalbuminemia, Hypoalbuminemia, and Albumin Replacement in a Sheep Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	4
496	A Fully Integrated Assay Panel for Early Drug Metabolism and Pharmacokinetics Profiling. <i>Assay and Drug Development Technologies</i> , 2020, 18, 157-179.	0.6	22
497	Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach. <i>Drug Metabolism and Disposition</i> , 2020, 48, 570-579.	1.7	7
498	Direct Comparison of Total Clearance Prediction: Computational Machine Learning Model versus Bottom-Up Approach Using In Vitro Assay. <i>Molecular Pharmaceutics</i> , 2020, 17, 2299-2309.	2.3	33
499	Calculating safety margins using total plasma concentration versus unbound plasma concentration - does it make a difference?. <i>Regulatory Toxicology and Pharmacology</i> , 2020, 115, 104709.	1.3	0
500	Drug Safety in Geriatric Patients: Current Status and Proposed Way Forward. <i>Drug Safety</i> , 2020, 43, 853-866.	1.4	4
501	The Impact of Infection and Inflammation on Drug Metabolism, Active Transport, and Systemic Drug Concentrations in Veterinary Species. <i>Drug Metabolism and Disposition</i> , 2020, 48, 631-644.	1.7	9
502	Interpretation of Drug Interaction Using Systemic and Local Tissue Exposure Changes. <i>Pharmaceutics</i> , 2020, 12, 417.	2.0	17
503	Development of clinically effective formulations for anticancer applications: why it is so difficult?. , 2020, , 599-723.		0
504	Considerations for the optimal management of antibiotic therapy in elderly patients. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 22, 325-333.	0.9	27
505	Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. <i>European Journal of Cancer</i> , 2020, 129, 117-122.	1.3	12
506	Challenging the Relevance of Unbound Tissue-to-Blood Partition Coefficient (K <sub>puu</sub> ) on Prediction of Drug-Drug Interactions. <i>Pharmaceutical Research</i> , 2020, 37, 73.	1.7	6
507	Protein Binding and Stability of Drug Candidates: The Achilles' Heel in In Vitro Potency Assays. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2020, 45, 427-432.	0.6	1
508	Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 12156-12170.	2.9	56
509	Dexmedetomidine Improves Cardiovascular and Ventilatory Outcomes in Critically Ill Patients: Basic and Clinical Approaches. <i>Frontiers in Pharmacology</i> , 2019, 10, 1641.	1.6	36
510	Pharmacokinetic-Based Drug-Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 1663-1681.	2.0	29
511	Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients With End-Stage Renal Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 866-873.	2.3	7

#	ARTICLE	IF	CITATIONS
512	Does <i>In Vitro</i> Potency Predict Clinically Efficacious Concentrations?. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 298-305.	2.3	26
513	Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients. <i>Frontiers in Pharmacology</i> , 2020, 11, 340.	1.6	11
514	Characterization of plasma protein binding in two mouse models of humanized liver, PXB mouse and humanized TK-NOG mouse. <i>Xenobiotica</i> , 2021, 51, 51-60.	0.5	4
515	Impact of interleukin-6 on drug transporters and permeability in the hCMEC/D3 blood-brain barrier model. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 397-409.	1.0	8
516	Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 144-152.	0.8	3
517	Validated LC-MS/MS method for quantitation of total and free mycophenolic acid concentration and its application to a pharmacokinetic study in pediatric renal transplant recipients. <i>Biomedical Chromatography</i> , 2021, 35, e4989.	0.8	5
518	Serum albumin: clinical significance of drug binding and development as drug delivery vehicle. <i>Advances in Protein Chemistry and Structural Biology</i> , 2021, 123, 193-218.	1.0	35
519	Pharmacokinetic changes of clozapine and norclozapine in a rat model of non-alcoholic fatty liver disease induced by orotic acid. <i>Xenobiotica</i> , 2021, 51, 324-334.	0.5	8
520	Clinical Pharmacokinetics of Daptomycin. <i>Clinical Pharmacokinetics</i> , 2021, 60, 271-281.	1.6	20
521	Canine orosomucoid (alpha-1 acid glycoprotein) variants and their influence on drug plasma protein binding. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2021, 44, 116-125.	0.6	1
522	Pharmacology of Aging. , 2021, , 249-277.		0
523	Principles of pharmacokinetics and pharmacodynamics. , 2021, , 219-242.		0
524	Holistic Assessment of Compound Properties—In Vitro to In Vivo Pharmacology. , 2021, , .		0
525	Drug Binding to Plasma Proteins. , 2021, , 1-12.		0
526	Androgen Misuse and Abuse. <i>Endocrine Reviews</i> , 2021, 42, 457-501.	8.9	41
527	Optimization of Micafungin Dosage for Chinese Patients with Sepsis in the Intensive Care Unit Based on a Population Pharmacokinetic-Pharmacodynamic Analysis. <i>Pharmaceutical Research</i> , 2021, 38, 67-77.	1.7	2
528	Nonspecific Binding Considerations in the Rational Design and Development of Small Molecule COVID-19 Therapeutics. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 294-296.	2.3	4
529	Low Serum Albumin Level Is a Risk Factor for Delayed Methotrexate Elimination in High-Dose Methotrexate Treatment. <i>Annals of Pharmacotherapy</i> , 2021, 55, 1195-1202.	0.9	9

#	ARTICLE	IF	CITATIONS
530	Biodistribution of iron-oxide-stabilized 99mTc- ZrO2 nanoparticles in rabbit using honey as a capping agentâ€”microwave-assisted solâ€”gel approach. Journal of Sol-Gel Science and Technology, 2021, 98, 95-112.	1.1	4
531	Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates. Pharmaceutical Research, 2021, 38, 415-428.	1.7	20
532	A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	7
533	Successful and Unsuccessful Prediction of Human Hepatic Clearance for Lead Optimization. Journal of Medicinal Chemistry, 2021, 64, 3546-3559.	2.9	29
534	Pharmacokinetic drug interactions between antiseizure medications and drugs for comorbid diseases in children with epilepsy. Expert Opinion on Drug Metabolism and Toxicology, 2021, 17, 595-610.	1.5	0
535	Matrix Effects of the Hydroethanolic Extract of Calyces of Physalis peruviana L. on Rutin Pharmacokinetics in Wistar Rats Using Population Modeling. Pharmaceutics, 2021, 13, 535.	2.0	7
536	Sex and Gender Differences in Clinical Pharmacology: Implications for Transgender Medicine. Clinical Pharmacology and Therapeutics, 2021, 110, 897-908.	2.3	25
537	An update on the importance of plasma protein binding in drug discovery and development. Expert Opinion on Drug Discovery, 2021, 16, 1453-1465.	2.5	30
538	Pharmacokinetic/Pharmacodynamic Modeling of Spiramycin against Mycoplasma synoviae in Chickens. Pathogens, 2021, 10, 1238.	1.2	2
539	Impact of Changes in Free Concentrations and Drug-Protein Binding on Drug Dosing Regimens in Special Populations and Disease States. Journal of Pharmaceutical Sciences, 2021, 110, 3331-3344.	1.6	18
540	Plasma Protein Binding Drug Interactions. , 2021, , 1-11.		0
541	Prediction of Half-Life Extension of Peptides via Serum Albumin Binding: Current Challenges. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 163-172.	0.6	10
542	Consideration of the Unbound Drug Concentration in Enzyme Kinetics. Methods in Molecular Biology, 2021, 2342, 113-145.	0.4	2
543	Asymmetric flow field-flow fractionation as a multifunctional technique for the characterization of polymeric nanocarriers. Drug Delivery and Translational Research, 2021, 11, 373-395.	3.0	16
545	Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Singleâ€”Dose, Matched Caseâ€”Control Study. Clinical Pharmacology in Drug Development, 2021, 10, 707-717.	0.8	4
546	Wechselwirkungen zwischen Arzneimitteln. , 2004, , 529-542.		1
547	Drugâ€”Drug Interactions: Designing Development Programs and Appropriate Product Labeling. , 2011, , 21-56.		11
548	Pharmacokinetics and Pharmacodynamics in the Pediatric Patient. , 2017, , 441-516.		2

#	ARTICLE	IF	CITATIONS
549	Pharmacokineticâ€“Pharmacodynamic Modelling of Anesthetic Drugs. , 2017, , 117-145.		1
550	Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion. , 2018, , 15-47.		1
551	Pharmakokinetik, Pharmakogenetik und therapeutisches Drug Monitoring. , 2008, , 375-397.		1
552	Special Populations: Protein Binding Aspects. , 2011, , 67-71.		2
553	In Vitro/In Vivo Correlation for Drugâ€“Drug Interactions. , 2011, , 133-160.		4
554	Optimizing Drug Dosing in the ICU. , 2009, , 859-869.		2
555	Pharmakokinetik, Pharmakogenetik und therapeutisches Drug Monitoring. , 2012, , 441-464.		6
556	Pharmacotherapy for Mood and Anxiety Disorders. Mental Health and Illness Worldwide, 2017, , 427-453.	0.1	1
557	Hypoalbuminaemia and Altered Protein Binding. , 2018, , 73-99.		1
558	Drug Therapy in the Elderly. , 2007, , 375-388.		3
559	Prevalence and risk factors of baclofen neurotoxicity in patients with severely impaired renal function. Nefrologia, 2020, 40, 543-551.	0.2	2
560	Discovery and Development of Omecamtiv Mecarbil: A Novel Cardiac Myosin Activator for the Potential Treatment of Systolic Heart Failure. ACS Symposium Series, 2020, , 99-126.	0.5	1
561	Problems and pitfalls performing pharmacokinetic studies in children. Paediatric and Perinatal Drug Therapy, 2007, 8, 4-17.	0.6	5
562	Problems With Medicines in the Newborn Infant. , 2006, , 365-375.		1
563	Clinical implications of changes in hepatic drug metabolism in older people. Therapeutics and Clinical Risk Management, 2005, 1, 151-156.	0.9	28
564	Studies on Drug â€“ Human Serum Albumin Binding: The Current State of the Matter. Current Pharmaceutical Design, 2015, 21, 1817-1830.	0.9	70
565	Molecular Modeling Approaches for the Prediction of Selected Pharmacokinetic Properties. Current Topics in Medicinal Chemistry, 2019, 18, 2230-2238.	1.0	2
566	Impaired Tubular Secretion of Organic Solutes in Acute Kidney Injury. Kidney360, 2020, 1, 724-730.	0.9	1

#	ARTICLE	IF	CITATIONS
567	Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction. <i>World Journal of Nephrology</i> , 2015, 4, 330.	0.8	10
568	A review of pharmacokinetic and pharmacodynamic interactions with antipsychotics. <i>Mental Health Clinician</i> , 2016, 6, 21-27.	0.5	9
570	Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0149321.	1.4	1
571	Enantioresolution and Binding Affinity Studies on Human Serum Albumin: Recent Applications and Trends. <i>Chemosensors</i> , 2021, 9, 304.	1.8	12
573	Opioid Analgesic Drugs. , 2006, , 589-611.		0
575	Principles of Pharmacology. , 2007, , 81-95.		2
576	Use of Antibiotics in Pregnant Patients in the Intensive Care Unit. , 2007, , 168-182.		1
579	Drug Dosing in Patients with Acute Kidney Injury and in Patients Undergoing Renal Replacement Therapy. , 2009, , 1727-1730.		0
580	Principles of Pharmacology in the Critically Ill. , 2009, , 31-36.		0
581	Optimizing Drug Dosing in the ICU. , 2009, , 859-869.		0
582	Change in Prothrombin Time International Normalized Ratio due to Drug Interaction between Docetaxel and Warfarin. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2010, 36, 802-806.	0.0	0
584	Induction of Warfarin Metabolism by Rifabutin: A Case Report. <i>Iryo Yakugaku (Japanese Journal of)</i> Tj ETQq1 1 0.784314 rgBT <sub>1</sub> /Overlo	0.0	0
585	Pharmacokinetic Studies in Pregnant Women. , 2011, , 195-209.		0
586	General Principles of Pharmacokinetics and Pharmacodynamics. , 2011, , 1253-1264.		1
589	Pharmacologie et personnes ÃƒgÃ©es. RÃ©fÃ©rences En RÃ©animation, 2012, , 165-179.	0.0	0
590	Are We Sure We Are Using Drugs Correctly in Critical Patients?. , 2012, , 107-119.		0
593	PHARMACOVIGILANCE IN INDIA: PERSPECTIVES AND PROSPECTS. <i>Journal of Drug Delivery and Therapeutics</i> , 2013, 3, .	0.2	3
594	Drug-Drug Interactions: Regulatory and Theoretical Considerations, and an Industry Perspective. <i>RSC Drug Discovery Series</i> , 2015, , 263-282.	0.2	0



#	ARTICLE	IF	CITATIONS
595	Pharmacotherapy for Mood and Anxiety Disorders. <i>Mental Health and Illness Worldwide</i> , 2016, , 1-27.	0.1	0
596	Pharmakologische Grundlagen: Das Schicksal psychoaktiver Substanzen im menschlichen K�rper. , 2016, , 1-32.		0
597	Influence of acute normovolemic hemodilution on the potency and time course of action of rocuronium in rabbits. <i>Anesthesia and Pain Medicine</i> , 2016, 11, 273-279.	0.5	1
598	Pharmakologische Grundlagen: Das Schicksal psychoaktiver Substanzen im menschlichen K�rper. , 2018, , 341-364.		0
599	Chapter 7: Pharmacology. , 2018, , .		0
601	Serum Albumin Nanoparticles: Problems and Prospects. <i>Polymers</i> , 2021, 13, 3759.	2.0	38
602	In Vitro/In Vivo Correlation for Drug-Drug Interactions. , 2020, , 847-866.		0
603	Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. <i>Current Drug Metabolism</i> , 2020, 21, 866-884.	0.7	8
604	Medication therapy in older adults. , 2022, , 479-498.		0
605	Pharmacology of Aging. , 2020, , 1-30.		0
606	Pharmakokinetik von Tumorthapeutika bei normaler und eingeschr�nkter Nierenfunktion. , 2020, , 221-241.		0
607	Special Populations: Protein Binding Aspects. , 2020, , 765-772.		0
608	Integrated exposure‐response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 585-594.	1.1	6
609	Hypoglycemia possibly caused by CYP2C9-mediated drug interaction in combination with bucolome: a case report. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2021, 7, 39.	0.4	2
610	Pharmacokinetics in the Geriatric Population. , 2008, , 481-493.		0
613	Personalized Anesthesia for the Elderly. , 2021, , 327-349.		0
614	Population Pharmacokinetics of Intravenous Amoxicillin Combined With Clavulanic Acid in Healthy and Critically Ill Dogs. <i>Frontiers in Veterinary Science</i> , 2021, 8, 770202.	0.9	2
615	Variability of Tacrolimus Trough Concentration in Liver Transplant Patients: Which Role of Inflammation?. <i>Pharmaceutics</i> , 2021, 13, 1960.	2.0	2



#	ARTICLE	IF	CITATIONS
616	Drug-Drug Interactions With a Pharmacokinetic Basis. , 2021, , .		0
617	Pharmacokinetic and Pharmacodynamic Considerations. , 2020, , 108-112.		0
618	Optimized loading dose strategies for bedaquiline when restarting interrupted drug-resistant tuberculosis treatment. Antimicrobial Agents and Chemotherapy, 2022, , AAC0174921.	1.4	1
620	Impact of ageing on the pharmacokinetics and pharmacodynamics of the drugs. , 2022, , 241-261.		1
621	History of androgens and androgen action. Best Practice and Research in Clinical Endocrinology and Metabolism, 2022, 36, 101629.	2.2	4
622	Distribution and Transmembrane transport as the basis of proper Pharmacodynamics of an Antithrombotic drug " An Indolinone derivative. Research Journal of Pharmacy and Technology, 2022, , 1241-1244.	0.2	1
623	Altered peripheral factors affecting the absorption, distribution, metabolism, and excretion of oral medicines in Alzheimer's disease. Advanced Drug Delivery Reviews, 2022, 185, 114282.	6.6	4
626	Pharmacokinetics of free and total mycophenolic acid in pediatric and adult renal transplant recipients: exploratory analysis of the effects of clinical factors and gene variants. Basic and Clinical Pharmacology and Toxicology, 2022, , .	1.2	2
627	Drug-drug interactions involving antipsychotics and antihypertensives. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 285-298.	1.5	4
628	The importance of plasma protein and tissue binding in a drug discovery program to successfully deliver a preclinical candidate. Progress in Medicinal Chemistry, 2022, , 163-214.	4.1	5
629	Plasma Protein Binding Drug Interactions. , 2022, , 1019-1028.		0
630	Drug Binding to Plasma Proteins. , 2022, , 315-326.		0
631	Review and evaluation of vancomycin dosing guidelines for obese individuals. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 323-335.	1.5	2
632	Protein Binding in Translational Antimicrobial Development-Focus on Interspecies Differences. Antibiotics, 2022, 11, 923.	1.5	9
633	Comorbidities and the right dose: antipsychotics. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 507-518.	1.5	3
634	Pharmacologic therapies. , 2022, , 408-423.e7.		0
635	Elucidation of the binding mechanism of astragaloside IV derivative with human serum albumin and its cardiotoxicity in zebrafish embryos. Frontiers in Pharmacology, 0, 13, .	1.6	2
636	Characterization of plasma daptomycin in patients with serum highly glycosylated albumin and obesity. Journal of Infection and Chemotherapy, 2022, , .	0.8	0

#	ARTICLE	IF	CITATIONS
638	Potential drug-drug interaction between warfarin and norethindrone in adolescent females: A case series. <i>American Journal of Health-System Pharmacy</i> , 0, , .	0.5	1
639	Drug-drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 729-744.	1.5	1
640	A commentary on the use of pharmacoenhancers in the pharmaceutical industry and the implication for DMPK drug discovery strategies. <i>Xenobiotica</i> , 2022, 52, 786-796.	0.5	1
641	Plasma Protein Binding Refinement of the Extended Clearance Classification System: Subclasses for Predicting Hepatic Uptake or Renal Clearance for Classes 1B and 3B. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 0, , .	0.6	0
642	Predicting changes in the pharmacokinetics of CYP3A4-metabolized drugs in hepatic impairment and insights into factors driving these changes. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 261-273.	1.3	5
643	Turn On, Tune In, Turnover! Target Biology Impacts In Vivo Potency, Efficacy, and Clearance. <i>Pharmacological Reviews</i> , 2023, 75, 416-462.	7.1	2
644	Antithrombotic Management in Spine Surgery in the Elderly. , 2023, , 19-49.		0
645	Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical Practice. <i>Clinical Pharmacokinetics</i> , 2023, 62, 55-66.	1.6	3
647	Pathophysiologic changes in chronic heart failure affecting drug pharmacokinetics. , 2023, , 17-30.		0
648	Physiologically-Based Pharmacokinetic Modeling of Tenofovir Disoproxil Fumarate in Pregnant Women. <i>Current Drug Metabolism</i> , 2022, 23, 1115-1123.	0.7	1
649	Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19. <i>European Journal of Pharmaceutical Sciences</i> , 2023, 184, 106418.	1.9	1
650	Development and validation of a dosing nomogram for continuous infusion cloxacillin in infective endocarditis. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 965-974.	1.3	0
651	Hypoalbuminemia and Pharmacokinetics: When the Misunderstanding of a Fundamental Concept Leads to Repeated Errors over Decades. <i>Antibiotics</i> , 2023, 12, 515.	1.5	3
652	Importance of relative binding of bisphenol A and bisphenol S to plasma proteins for predicting their in vivo potencies. <i>Toxicology and Applied Pharmacology</i> , 2023, 466, 116477.	1.3	0
653	Development of a Novel Tool to Demystify Drug Distribution at Tissue-Blood Barriers. <i>ChemBioChem</i> , 0, , .	1.3	0
654	Developmental Pharmacology. , 2017, , 168-185.e2.		0
655	Safety and Tolerability of Antimicrobial Agents in the Older Patient. <i>Drugs and Aging</i> , 2023, 40, 499-526.	1.3	6
656	Biased computation of probability of target attainment for antimicrobial drugs. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 681-689.	1.3	4

#	ARTICLE	IF	CITATIONS
658	Anesthesia and Ancillary Drugs and the Neonate. , 2023, , 99-166.		0
659	General Principles of Pharmacologic Therapy. , 2023, , 1-18.		0
668	Design and Conduct of Pharmacokinetics Studies Influenced by Extrinsic Factors. , 2023, , 291-314.		0